| 8.77 0.31 (3.66%) | 09-26 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 11.58 | 1-year : | 13.53 |
| Resists | First : | 9.92 | Second : | 11.58 |
| Pivot price | 8.46 |
|||
| Supports | First : | 8.07 | Second : | 6.92 |
| MAs | MA(5) : | 8.52 |
MA(20) : | 8.14 |
| MA(100) : | 6.99 |
MA(250) : | 5.38 |
|
| MACD | MACD : | 0.2 |
Signal : | 0.2 |
| %K %D | K(14,3) : | 54.5 |
D(3) : | 52.1 |
| RSI | RSI(14): 58.9 |
|||
| 52-week | High : | 9.92 | Low : | 2.35 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ TRVI ] has closed below upper band by 36.3%. Bollinger Bands are 60.9% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 12 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 8.93 - 8.98 | 8.98 - 9.01 |
| Low: | 8.14 - 8.19 | 8.19 - 8.23 |
| Close: | 8.7 - 8.77 | 8.77 - 8.84 |
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase IIb/III clinical trial for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.
Wed, 24 Sep 2025
Trevi Therapeutics (TRVI): Valuation Spotlight Following RIVER Trial Data Presentation Announcement - simplywall.st
Sun, 21 Sep 2025
How Investors Are Reacting To Trevi Therapeutics (TRVI) Revealing Haduvio Phase 2a Data at ERS Congress - simplywall.st
Thu, 18 Sep 2025
Clinical Trial Results: Trevi's Breakthrough Chronic Cough Treatment Data to be Featured at European Congress - Stock Titan
Sun, 14 Sep 2025
Trevi Therapeutics (TRVI): Assessing Valuation as Analyst Coverage Highlights Haduvio’s Potential in Chronic Cough Market - simplywall.st
Thu, 28 Aug 2025
Trevi Therapeutics to Participate in Upcoming September Conferences - PR Newswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 122 (M) |
| Shares Float | 91 (M) |
| Held by Insiders | 0.7 (%) |
| Held by Institutions | 93.2 (%) |
| Shares Short | 11,680 (K) |
| Shares Short P.Month | 10,160 (K) |
| EPS | -0.42 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.62 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -22.9 % |
| Return on Equity (ttm) | -35.8 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.43 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -43 (M) |
| Levered Free Cash Flow | -26 (M) |
| PE Ratio | -20.89 |
| PEG Ratio | 0 |
| Price to Book value | 5.38 |
| Price to Sales | 0 |
| Price to Cash Flow | -25.03 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|